Factors which cause post-menopausal early stage breast cancer patients to have joint symptoms

August 12, 2008

Previous use of hormone replacement therapy (HRT), hormone-receptor positivity, previous chemotherapy, obesity, and treatment with anastrozole versus tamoxifen are all risk factors for joint symptoms (eg, arthralgia and arthritis) in postmenopausal women with breast cancer on endocrine treatment, according to a retrospective exploratory analysis of patients enrolled in the ATAC trial*, published early Online and in the September edition of The Lancet Oncology.

Dr Ivana Sestak and Dr Jack Cuzick (Cancer Research UK, London, UK) and colleagues investigated the importance of a range of risk factors for joint symptoms in patients enrolled in the ATAC trial, in which postmenopausal women with breast cancer were randomly assigned to either an aromatase inhibitor (anastrozole) or tamoxifen. The authors also examined whether the importance of these risk factors varied according to treatment. 5433 women who were enrolled in the ATAC trial and did not report joint symptoms at entry were included in the analysis, which was based on data from case reports for these patients.

41.1% (777 of 1937) of women who had previously used HRT reported joint symptoms compared with 28.6% (1001 of 3496) of women who had not used HRT. In women with hormone-receptor-positive tumours, 33.9% (1556 of 4596) reported joint symptoms compared with 27.7% (124 of 448) who had hormone-receptor-negative tumours. Women who received previous chemotherapy also reported significantly more joint symptoms than those who had not (39.2% [461 of 1176] vs 30.9% [1317 of 4257]). Obesity also had a role in the onset of joint symptoms, with significantly more joint symptoms being reported with increasing BMI (37.2% [504 of 1460] for BMI >30 kg/m2 vs 31.3% [602 of 2021] for BMI 25?? kg/m2 vs 31.0% [592 of 1950] for BMI <25 kg>

These risk factors are all potentially linked with greater decreases in oestrogen concentration when patients start taking endocrine treatment, and oestrogen deficiency has been associated with joint symptoms in several different settings. The effects of these risk factors are additive, and therefore need to be taken into account when preparing women for the use of aromatase inhibitors. Dr Sestak concludes: "Awareness of risk factors for joint symptoms will help both clinicians and patients to anticipate and manage these symptoms and ensure optimum adherence to endocrine treatment".
-end-
Dr Jack Cuzick, Cancer Research UK, Centre for Epidemiology, Mathematics, and Statistics, Wolfson Institute of Preventive Medicine, London, UK
jack.cuzick@cancer.org.uk
Tel: +44 (0)20 7014 0227

Notes to Editors:

*The ATAC (Arimidex [anastrozole] Tamoxifen Alone or in Combination) trial was a double-blind, randomised clinical trial in which anastrozole and tamoxifen were compared in over 9000 postmenopausal women with early-stage breast cancer.

Lancet

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.